Endeavor

Moffitt Researchers Find Breakthrough Treatment for Aggressive Blood Cancers

Promising combo therapy and innovative tracking techniques offer new hope for patients

Moffitt Study Finds New Genetic Clues to Resistance in Multiple Myeloma Treatments

Study reveals genetic markers that predict treatment resistance, offering potential for more personalized therapy plans

New CAR T-Cell Therapy Shows Promising Results for Advanced Multiple Myeloma

Early trial results show high success rates and manageable side effects

Personalized Vaccine Shows Promise in Early HER2-Positive Breast Cancer

Dendritic cell vaccine uses immune cells collected from the patient, which are enhanced in the lab and injected directly into the primary breast tumor

New Treatment Combination Improves Outcomes for Relapsed or Refractory Large B-Cell Lymphoma

Patients who received the mosunetuzumab-polatuzumab combination had a 78% response rate

Drug Aims To Improve Transplant Success for Myelofibrosis Patients

Study shows giving patients fedratinib is safe and could help reduce chance of relapse

Moffitt Study Explores Key Risk Factors To Better Personalize CAR T-Cell Therapy

The study analyzed ide-cel to help physicians intervene and reduce toxicities in multiple myeloma patients

Drug Offers New Option for Patients With Rare Blood Disorders in ‘No Man’s Land’

Fedratinib is approved to treat myelofibrosis and could be effective in myelodysplastic/myeloproliferative neoplasms

Largest Comprehensive Study Compares Efficacy of CAR T Products for Multiple Myeloma

Cilta-cel demonstrates greater effectiveness than ide-cel but carries higher toxicities, study finds